Encapsulated cells producing cytochrome p450 and methods of use thereof
AssigneePharmaCyte Biotech, Inc.
InventorsKenneth L. WAGGONER, Gerald W. CRABTREE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions to treat solid tumors. In one embodiment, the method of treating a solid tumor in a patient includes administering at the tumor site a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule and administering a prodrug which is activated by cytochrome P450, wherein the prodrug is administered at least three or more cycles, and wherein each cycle comprises three consecutive daily administration.
Claims36
A method of treating a solid tumor in a subject in need thereof comprising:
- administering at the site of the tumor in the subject a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule;
- and
- administering to the subject a prodrug which is activated by cytochrome P450, wherein the prodrug is administered at least three or more cycles and wherein each cycle comprises administration for three consecutive days.
A HEK293 cell stably expressing cytochrome P450 2B1 isoform.
A syringe comprising:
- a plurality of capsules contained within the syringe, each capsule comprising a plurality of cytochrome P450 producing cells, and wherein capsule membrane is permeable to a prodrug.
A method of treating a subject suffering from pancreas cancer that is resistant to gemcitabine and nab-paclitaxel comprises administering at the tumor site a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule, and administering a prodrug which is activated by cytochrome P450.
A method of treating a subject suffering from pancreas cancer that is resistant to gemcitabine and nab-paclitaxel comprises administering at the tumor site a therapeutically effective amount of cytochrome P450 producing cells encapsulated in a capsule, and administering a prodrug which is activated by cytochrome P450, wherein the prodrug is administered at least three or more cycles, and wherein each cycle comprises three consecutive daily administrations.
Dependencies are inferred from the claim text.